



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Acumapimod

Item No. 25832

CAS Registry No.: 836683-15-9
Formal Name: 3-[5-amino-4-(3-cyanobenzoyl)-1H-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide
Synonym: BCT-197
MF: $C_{22}H_{19}N_5O_2$
FW: 385.4
Purity: $\geq 98\%$
UV/Vis.: λ_{max} : 212, 315 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Acumapimod is supplied as a crystalline solid. A stock solution may be made by dissolving the acumapimod in the solvent of choice, which should be purged with an inert gas. Acumapimod is soluble in the organic solvent DMSO.

Description

Acumapimod is an inhibitor of p38 α MAPK ($IC_{50} = <1 \mu\text{M}$).¹ It increases survival and reduces the number of macrophages in bronchoalveolar lavage fluid (BALF) in a mouse model of infection with influenza H1N1 A/PR/8/34 when administered at a dose of 6 mg/kg.² Acumapimod (3 mg/kg) reduces the number of neutrophils in BALF in rats exposed to aerosolized LPS alone or in combination with tobacco smoke.³ It also inhibits airway epithelium mucus hyperplasia in rats exposed to aerosolized LPS and tobacco smoke ($ED_{50} = 0.3 \text{ mg/kg}$).

References

1. Fryszman, O.M., Lang, H., Lan, J., *et al.* 5-membered heterocycle-based p38 kinase inhibitors. *Triad Therapeutics, Inc.* **WO 2005/009973 A1** (2005).
2. Growcott, E.J., Bamba, D., Galarneau, J.R., *et al.* The effect of P38 MAP kinase inhibition in a mouse model of influenza. *J. Med. Microbiol.* **67**(3), 452-463 (2018).
3. Parkin, J.M. and Hardaker, E.L. Effects of acumapimod (bct197), an oral p38 inhibitor, on tobacco smoke and lipopolysaccharide-induced lung inflammation in a corticosteroid-resistant rat model. *Am. J. Respir. Crit. Care Med.* **195**:A6305, (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/26/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM